<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05044468</url>
  </required_header>
  <id_info>
    <org_study_id>2019-0237</org_study_id>
    <secondary_id>NCI-2021-08954</secondary_id>
    <secondary_id>2019-0237</secondary_id>
    <nct_id>NCT05044468</nct_id>
  </id_info>
  <brief_title>EXPAREL or Lidocane as Local Anesthetic in Patients Undergoing Pleuroscopy With Pleural Biopsy and Indwelling Pleural Catheter Placement</brief_title>
  <official_title>A Randomized Blinded Controlled Trial of EXPAREL vs 1% Lidocane as Local Anesthetic in Patients Undergoing Pleuroscopy With Pleural Biopsy and Indwelling Pleural Catheter Placement</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>M.D. Anderson Cancer Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase II trial investigates the effect of EXPAREL compared to lidocane as a local&#xD;
      anesthetic in patients who are undergoing pleuroscopy with pleural biopsy and indwelling&#xD;
      pleural catheter placement. This trial aims to see whether EXPAREL or lidocane is able to&#xD;
      make patients more comfortable.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVE:&#xD;
&#xD;
      I. To compare Global chest pain score (measured on the Visual Analog Scale [VAS] scale)&#xD;
      post-procedure and post procedural chest pain (measured on the numerical rating scale), at&#xD;
      the time of discharge from recovery between liposomal bupivacaine (EXPAREL) and 1 percent&#xD;
      lidocaine.&#xD;
&#xD;
      SECONDARY OBJECTIVES:&#xD;
&#xD;
      I. To compare post procedural chest pain (measured on the numerical rating scale) at the time&#xD;
      of discharge from recovery, 24 hours and 48 hours post procedure between EXPAREL and 1&#xD;
      percent lidocaine.&#xD;
&#xD;
      II. To assess the change in global chest pain score (measured on the VAS scale) from baseline&#xD;
      to the time of discharge from recovery, and post procedural chest pain (measured on the&#xD;
      numerical rating scale) from baseline over time between EXPAREL and 1 percent lidocaine.&#xD;
&#xD;
      III. To compare the number of narcotics within 24 hours, and from 24 to 48 hours post&#xD;
      procedure between EXPAREL and 1 percent lidocaine.&#xD;
&#xD;
      OUTLINE: Patients are randomized to 1 of 2 groups.&#xD;
&#xD;
      GROUP A: Patients receive liposomal bupivacaine via injection into the intercostal nerve&#xD;
      block.&#xD;
&#xD;
      GROUP B: Patients receive lidocaine via injection into the pleuroscopy port incision sites&#xD;
      and indwelling pleural catheter site.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 23, 2021</start_date>
  <completion_date type="Anticipated">April 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">April 1, 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Global chest pain score</measure>
    <time_frame>Through study completion, an average of 1 year</time_frame>
    <description>Will be evaluated by the Global chest pain score at the time of discharge from recovery area using a Visual Analog Scale 0-100 and represents the pain experienced by the patient.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Malignant Pleural Neoplasm</condition>
  <arm_group>
    <arm_group_label>Group A (liposomal bupivacaine)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive liposomal bupivacaine via injection into the intercostal nerve block.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B (lidocaine)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients receive lidocaine via injection into the pleuroscopy port incision sites and indwelling pleural catheter site.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lidocaine</intervention_name>
    <description>Given via injection</description>
    <arm_group_label>Group B (lidocaine)</arm_group_label>
    <other_name>.omega.-Diethylamino-2,6-dimethylacetanilide</other_name>
    <other_name>2-(Diethylamino)-2'',6''-acetoxylidide</other_name>
    <other_name>Cuivasil</other_name>
    <other_name>Duncaine</other_name>
    <other_name>Leostesin</other_name>
    <other_name>Lidothesin</other_name>
    <other_name>Lignocaine</other_name>
    <other_name>Rucaina</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Liposomal Bupivacaine</intervention_name>
    <description>Given via injection</description>
    <arm_group_label>Group A (liposomal bupivacaine)</arm_group_label>
    <other_name>Bupivacaine Liposome Injectable Suspension</other_name>
    <other_name>Exparel</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Questionnaire Administration</intervention_name>
    <description>Ancillary studies</description>
    <arm_group_label>Group A (liposomal bupivacaine)</arm_group_label>
    <arm_group_label>Group B (lidocaine)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Referral to pulmonary services for pleuroscopy with biopsies and indwelling pleural&#xD;
             catheter (IPC) placement&#xD;
&#xD;
          -  Age &gt; 18&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Inability to provide informed consent&#xD;
&#xD;
          -  Study subject has any disease or condition that interferes with safe completion of the&#xD;
             study including:&#xD;
&#xD;
               -  Allergic reaction to EXPAREL&#xD;
&#xD;
          -  Need for pleurodesis&#xD;
&#xD;
          -  No placement if IPC&#xD;
&#xD;
          -  Previous ipsilateral thoracic surgery&#xD;
&#xD;
          -  Allergies to lidocaine or other local anesthetics, narcotics, non-steroidal&#xD;
             anti-inflammatory drugs (NSAIDs) or acetaminophen&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Advanced liver disease where the clinician deems the procedure unsafe&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Horiana Grosu</last_name>
    <role>Principal Investigator</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>M D Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Horiana Grosu</last_name>
      <phone>713-792-6238</phone>
      <email>hbgrosu@mdanderson.org</email>
    </contact>
    <investigator>
      <last_name>Horiana Grosu</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mdanderson.org</url>
    <description>University of Texas MD Anderson Cancer Center Website</description>
  </link>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>September 2, 2021</study_first_submitted>
  <study_first_submitted_qc>September 13, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 14, 2021</study_first_posted>
  <last_update_submitted>September 21, 2021</last_update_submitted>
  <last_update_submitted_qc>September 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 23, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pleural Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lidocaine</mesh_term>
    <mesh_term>Bupivacaine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

